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Topic 
– Why scale matters in the study of the feasibility of 
cognitive bio-enhancement programs 
▪ If resources are enough to achieve the goals 
▪ Technologies involved have passed a rigorous evaluation 
▪ Resources are well dimensioned, specific, cost-efficient and 
validated 
 
– Moral implications 
▪ Social cooperation and resources distribution 




– Viability  of cognitive bio-enhancements programs 
– Scenarios  (primary, high school, university) 
– Careful assessment of bio-enhancement technologies 
– Inequalities in access to educational resources  
– Scales of interventions 
– Social context, institutional and cultural environment 
– Socio-technical prospective  
– Dystopian objections 
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Aim and objectives 
• Study the viability of cognitive bio-
enhancements programs 
– in verisimilar scenarios (primary, high school, university) 
– with reliable devices and substances (for medical uses) 
– considering the differences in initial conditions  
▪ educational resources and cultural environment 
▪ extracurricular learning support and inequalities in access to IT 
– considering scales of interventions  
– socio-technical prospective and dystopian objections 
Background 
• Cognitive bio-enhancement as a challenge for 
moral deliberation in the present 
– Short repertoire of technological options for humans 
▪ Not affordable for generalized use, except in clinical context 
▪ Most part remain as experimental, before the "proof of concept" 
phase 
▪ A few of them (neuromodulators) will be safe, specific and 
validated for medical uses 
 
– Who could be eligible for its benefits? 
▪ Childs, teenagers, students in universities, athletes… 
▪ Most likely, only very specific individuals/cases 
▪ Physiological approaches focused on pharmaceutical research 
 
Background 
Four main types of physiological interventions: 
 Genetic, pharmacologic, electro-magnetic, and surgical  
– Surgical (primary physiological target is CNS):  
(i) implantation of neuroprostheses, including brain-computer 
interfaces (“bionics”) 
(ii) intracranial grafting or implantation of cells (neural, non-neural, or 
embryonic stem cells) for tissue repair or cell-containing devices 
for the local delivery of bioactive compounds  
(iii) intracranial gene transfer techniques to enhance or dampen 
protein expression for cure  
(iv) techniques of direct surgical, or electrical, stimulation of defined 
brain areas for the functional treatment of nervous disorders such 
as epilepsy. 
– Over sixty studies have reported significant improvements in speed and 
accuracy in a variety of tasks involving perceptual, motor, and executive 
processing.  
– Two basic categories of enhancement mechanisms: 
▪ direct modulation of a cortical region or network that leads to more efficient 
processing,  
▪ and addition-by-subtraction (disruption of processing which competes or distracts 
from task performance). 
– Potential applications of TMS cognitive enhancement for accelerated skill 
acquisition in healthy individuals 
→ further refinements in the application of TMS to cognitive enhancement can still be 
made | questions remain regarding the mechanisms underlying the observed effects. 
NeuroImage 85 (2014) 961–970 - 
http://dx.doi.org/10.1016/j.neuroimage.2013.06.007  
Direct-to-consumer TMS devices 
• Only 1 deep transcranial magnetic stimulation 
machine in Spain in Oct. 2015: (1, 2, 3) 
– Israeli company (Brainsway LTD) has the patent and markets it 
under "draconian" conditions: 
▪ Brainsway does not sell the equipment: it rents for 3 years 
– 60.000 - 110.000 EUR/year 
– Extra amount  if >40 patients 
– 150 – 300 EUR/ session 
– 20 sessions in 4 – 12 weeks  (usual treatment) = 3.900 EUR 
– Extended fraudulent offer on the Internet in 2016-2017 
▪ Risks of direct to consumer TMS devices (ej. 1, vs ej. 2) 
→ Maslen, H., Douglas, T., Cohen Kadosh, R., Levy, N., & Savulescu, J. (2014). The 
regulation of cognitive enhancement devices: extending the medical model. Journal of 
Law and the Biosciences, 1(1), 68–93. http://doi.org/10.1093/jlb/lst003 
     → Thync Vibes ($299) 
Advertising based on testimonies (and some refs.) 
http://www.brainsway.com/researchers-portal  
Lack of regulation for non-clinical use of TMS 
http://www.oxfordmartin.ox.ac.uk/downloads/briefings/Mind_Machines.pdf  
Proposal: Cognitive enhancement devices (CEDs)—such as transcranial direct current 
stimulators (tDCS) and transcranial magnetic stimulators (TMS)—should be regulated 
under medical devices legislation (for instance, the Medical Devices Directive (MDD) 
within the European Union). 
  Maslen, H., Douglas, T., Cohen Kadosh, R., Levy, N., & Savulescu, J. (2014).  
The regulation of cognitive enhancement devices: extending the medical model.  
Journal of Law and the Biosciences, 1(1), 68–93. http://doi.org/10.1093/jlb/lst003  
Lack of regulation for non-clinical use 
→ Definition of a CED / distinction treatment - enhancement 
– Maslen et al. (1) minimize the importance given to the treatment-
enhancement distinction: 
▪ If some devices are misclassified as therapeutic devices, this will not have 
major implications for their regulation: What matters are risks and benefits. 
– The European Commission's proposed creation of Annex XV for implantable and 
other invasive devices for which the manufacturer claims only a non-medical 
purpose (2): should include non-invasive neuromodulation for non-medical purposes 
– Maslen, Savulescu et al.: There is a wealth of scientific research that provides proof 
of concept for the cognitive enhancing effects of tDCS and TMS techniques. 
– De Ridder, Vanneste, and Focquaert (3): there is currently ‘no substantive evidence 
that CEDs produce lasting effects outside of research and clinical settings’. 
(1) Maslen, H., Douglas, T., Cohen Kadosh, R., Levy, N., & Savulescu, J. (2015).  
The regulation of cognitive enhancement devices: refining Maslen et al.’s model.  
Journal of Law and the Biosciences, lsv029. http://doi.org/10.1093/jlb/lsv029  
(2) http://ec.europa.eu/health/medical-devices/files/revision_docs/proposal_2012_542_en.pdf 
(3) Dirk De Ridder, Sven Vanneste & Farah Focquaert, Outstanding Questions Concerning The Regulation Of 
Cognitive Enhancement Devices, 1 J. L. & Biosci. 316–21 (2014) 
Example #1 
• Only 1 student undergoes medical treatment 
for cognitive enhancement in a secondary 
school center (20 groups and 600 students) 
▪ Scale ratio: 1:600 
▪ Proportion: 0.17%  
 
– Projection (Spain, 2014-2015): 
▪ 13.483 stud. in the country (Total: 8.090.017 non univ. students) 
▪ If cost/tto. = 5.000 EUR, total cost= 67.415.000 EUR 





– The last alternative to compensate biological, genetic or 
neurophysiological impairments 
– Reasonable expectations about restoring average 
cognitive functions, rather than improving or enhancing 
– When the technologies involved are still experimental 
▪ Risk evaluation 
▪ Cost-efficiency 
▪ Priorities compatible with general interest 
▪ Informed consent 
 
 
Impact of the Great Recession on 
spanish educational system 
– 30.000 profs. less than in 2013 
– 1.036.000 stud. more in the period of 
compulsory schooling 
 
Changes in the ratio 
 From 25 to 30 stud./class in Primary school 
 30 → 36 stud./class Secondary school 
 37 → 42 stud/ class in pre-universitary 
 
Consequences 
• Deterioration in key indicators (success ratio, 
dropout rate, average level in higher 
education…) 
• Increased risk of social conflict, work stress and 
discomfort among professionals  
• Lower perception of quality  
• Reduction of opportunities for the next 
generations 
Students under special support programs 
Datos y cifras Ministerio de Educación, Cultura y Deporte. Curso escolar 2015/2016.  
http://www.mecd.gob.es/servicios-al-ciudadano-mecd/dms/mecd/servicios-al-ciudadano-
mecd/estadisticas/educacion/indicadores-publicaciones-sintesis/datos-cifras/Datosycifras1617esp.pdf 
Teachers in the Andalusian educational system 
Estadísticas de la Consejería de educación, Junta de Andalucía. Datos estimativos 2016-2017.  
http://www.juntadeandalucia.es/educacion/webportal/ishare-servlet/content/b2ad15b9-
959a-4ad3-96f6-ff1c560dae64 
Reduction of teachers in Andalusia  (2011-2016) 
Estadísticas de la Consejería de educación, Junta de Andalucía. Datos estimativos 2016-2017.  
http://www.juntadeandalucia.es/educacion/webportal/ishare-servlet/content/b2ad15b9-
959a-4ad3-96f6-ff1c560dae64 
Ministerio de Educación y  Ciencia. Las cifras de la educación en España. 
Estadística e indicadores. 2004.  http://debateeducativo.mec.es/pdf/anexo.pdf  
Socio-technical prospective and dystopian objections 
Williams, S. J., Coveney, C. M., & Gabe, J. (2013). Medicalisation or customisation? Sleep, enterprise and enhancement in the 
24/7 society. Social Science & Medicine, 79(0), 40–47. http://doi.org/10.1016/j.socscimed.2012.07.017  
– Sociological research on the medicalisation of sleep 
▪ Prospective ‘customisation’ of sleep in the 24/7 society 
▪ How does it relate to the medicalisation of sleep 
 
– Extended use of drugs and technologies design to 
customize our sleep patterns and practices to fit around the 
escalating temporal demands of daily life,  
▪ As helping remedy to compensate the increasing misalignment 
between biological and social time.  
▪ Improving/optimise safety, productivity and performance in late 
modern society, where alertness is prized, sleepiness is 
problematized and vigilance is valorised.  
▪ Relations between the biomedicalisation/customisation of sleep and a 
research agenda on the biopolitics of sleep and wakefulness. 
Elements of dystopian objection in N. Agar 
N. Agar, Humanity's end: why we should reject radical 
enhancement. Cambridge, MA: MIT Press, 2010: 11. 
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